An analysis of electronic health records from over one million people with type 2 diabetes and no prior diagnosis of dementia found that semaglutide use was associated with a 40 to 70% reduced risk developing dementia over three years, depending on the comparator medication, with the greatest benefit seen when compared to insulin
5 Current clinical trials In a recent press release, the results from the phase 2 study of AMG133 ( maridebart cafraglutide or MariTide ) are revealed to induce a substantial weight loss following 52 weeks treatment
Clinical trials have demonstrated significant weight loss benefits with semaglutide, making it a highly sought-after medication since it has been approved by FDA
Queensland-based Business consultant Phillip Beresford is worried too
Your prescriber will individualize both the route (IV or IM) and the timetable based on your weight, kidney function, and overall clinical picture
I will likely be using this product for the rest of my life